Musa F - Search Results

1

Cross-Sectional Study of the Impact of a Natural Disaster on the Delivery of Gynecologic Oncology Care.

David-West G, Musa F, Frey MK, Boyd L, Pothuri B, Curtin JP, Blank SV. David-West G, et al. Among authors: musa f. Disaster Med Public Health Prep. 2015 Dec;9(6):605-8. doi: 10.1017/dmp.2015.83. Epub 2015 Jul 9. Disaster Med Public Health Prep. 2015. PMID: 26155945

2

Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium?

Musa F, Frey MK, Im HB, Chekmareva M, Ellenson LH, Holcomb K. Musa F, et al. Am J Obstet Gynecol. 2012 Nov;207(5):417.e1-6. doi: 10.1016/j.ajog.2012.06.051. Epub 2012 Jun 29. Am J Obstet Gynecol. 2012. PMID: 22840974

3

A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.

Musa F, Blank S, Muggia F. Musa F, et al. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):215-24. doi: 10.1517/17425255.2013.758249. Expert Opin Drug Metab Toxicol. 2013. PMID: 23320990 Review.

4

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.

Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ. Korets SB, et al. Among authors: musa f. Gynecol Oncol. 2014 Feb;132(2):468-73. doi: 10.1016/j.ygyno.2013.11.027. Epub 2013 Dec 4. Gynecol Oncol. 2014. PMID: 24316308 Free PMC article.

5

Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?

Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Frey MK, et al. Among authors: musa f. Cancer. 2016 Mar 15;122(6):859-67. doi: 10.1002/cncr.29859. Epub 2016 Jan 27. Cancer. 2016. PMID: 26938270 Free article.

6

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Musa F, et al. Mol Cancer Ther. 2016 Jul;15(7):1557-67. doi: 10.1158/1535-7163.MCT-15-0926. Epub 2016 May 16. Mol Cancer Ther. 2016. PMID: 27196780 Free PMC article.

7

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A. Musa F, et al. Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5. Gynecol Oncol. 2017. PMID: 27931751 Clinical Trial.

8

Neoadjuvant chemotherapy in patients with advanced endometrial cancer.

Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, Curtin JP, Pothuri B. Khouri OR, et al. Among authors: musa f. Cancer Chemother Pharmacol. 2019 Aug;84(2):281-285. doi: 10.1007/s00280-019-03838-x. Epub 2019 Apr 12. Cancer Chemother Pharmacol. 2019. PMID: 30980132

9

Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.

Blank SV, Huh WK, Bell M, Dilley S, Hardesty M, Hoskins ER, Lachance J, Musa F, Prendergast E, Rimel BJ, Shahin M, Valea F. Blank SV, et al. Among authors: musa f. Gynecol Oncol. 2023 Apr;171:76-82. doi: 10.1016/j.ygyno.2023.02.008. Epub 2023 Feb 22. Gynecol Oncol. 2023. PMID: 36827841

10

A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.

Pothuri B, Sawaged Z, Karpel HC, Li X, Lee J, Musa F, Lutz K, Reese E, Blank SV, Boyd LR, Curtin JP, Goldberg JD, Muggia FM. Pothuri B, et al. Among authors: musa f. Gynecol Oncol. 2024 Nov;190:209-214. doi: 10.1016/j.ygyno.2024.07.682. Epub 2024 Sep 3. Gynecol Oncol. 2024. PMID: 39232408 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters